Medrio is the leading provider of eClinical technology for pharma, device, and diagnostics clinical trials to pharmaceutical, biotech, medical device, diagnostics, and animal health markets. In July, Medrio announced that it and Avance Clinical, the leading Australian contract research organization for biotechs, had reached the milestone of supporting 150 clinical trials together. Medrio and Avance Clinical’s successful partnership began in 2012 on a Phase I study with 103 patients and 14 sites, with Avance Clinical being Medrio’s first partner in Australia.

“Medrio has always been a wonderful partner to Avance Clinical,” says Yvonne Lungerhausen, CEO of Avance Clinical. “We are always impressed by not only their speed and flexibility but also their support. We know that if we have a question or need assistance that it will be addressed immediately and resolved quickly. Our partnership continues to flourish through ongoing clinical trials. We also recently had a great conversation with Medrio on their podcast, Trial Talks, about Australia’s unique position in the midst of Covid-19. I look forward to the continued success and growth of our partnership.”

In July Medrio launched Trial Talks, a clinical trials podcast series. Hosted by Medrio thought leaders, Trial Talks season one will focus on industry trends and challenges, unique solutions, and the perseverance of the industry through one of its toughest challenges, Covid-19. Trial Talks season 1, episode 1, “Why Clinical Trials are Thriving in Australia” will focus on how Avance Clinical prepared for the pandemic, what tools they leveraged that allowed trial continuation, and why clinical trials are currently thriving in the region.

“I have always been data-driven, and reaching the 150 trials milestone speaks volumes about Medrio and Avance’s relationship,” says Mike Novotny, Medrio CEO. “Trust is earned, and I would like to think that we have shown that we offer not only sophisticated clinical trial technology but also pride in our work. Our support team is available 24/7, and I am always proud to hear our customers speak so highly of them. At Medrio we always have the patients in mind. The faster we can get a trial up and running or provide support, the faster the patients in need will have the drugs, therapies, or devices that they need.”

Founded in 2005, the company’s cloud-based EDC (electronic data capture), Direct Data Capture, eConsent, and ePRO solutions deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient-reported outcome responses. Study sponsors and Contract Research Organizations have used Medrio extensively in clinical trials across a wide array of therapeutic areas, with notable success in oncology, infectious disease, and more. Medrio has extensive experience in all study phases and leads the market in early-phase trials.

The company serves over 600 customers globally. It is based in San Francisco. In addition to its office at Hacienda, Medrio has offices in India, Japan, Germany, and the United Kingdom.

For more information about Medrio, please visit www.medrio.com.